Global Liver Transplant Anti-Rejection Drugs Supply, Demand and Key Producers, 2023-2029

Global Liver Transplant Anti-Rejection Drugs Supply, Demand and Key Producers, 2023-2029

The global Liver Transplant Anti-Rejection Drugs market size is expected to reach $ 2446.4 million by 2029, rising at a market growth of 3.1% CAGR during the forecast period (2023-2029).

The driving forces for the development of anti-rejection drugs for liver transplantation mainly include the following aspects:

Disease treatment needs: Liver transplantation is an effective method to treat end-stage liver disease, but the occurrence of rejection after transplantation will seriously affect the success rate of transplantation and the patient's quality of life. Therefore, anti-rejection therapy is an important part of post-liver transplantation treatment and promotes the development of anti-rejection drugs for liver transplantation.

Technological progress: With the continuous development of biotechnology, genetic engineering and other technologies, scientists have been able to develop more effective anti-rejection drugs, such as cell therapy, biological agents, nitroglycerin and other new anti-rejection drugs. These drugs have better immunity. Regulatory effects and fewer adverse reactions are one of the important factors promoting the development of anti-rejection drugs for liver transplantation.

Clinical needs: Clinicians need safer and more effective anti-rejection drugs to increase the success rate of transplantation and improve the quality of life of patients. This is also the intrinsic driving force for the development of anti-rejection drugs for liver transplantation.

This report studies the global Liver Transplant Anti-Rejection Drugs production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Liver Transplant Anti-Rejection Drugs, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Liver Transplant Anti-Rejection Drugs that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Liver Transplant Anti-Rejection Drugs total production and demand, 2018-2029, (K Units)

Global Liver Transplant Anti-Rejection Drugs total production value, 2018-2029, (USD Million)

Global Liver Transplant Anti-Rejection Drugs production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global Liver Transplant Anti-Rejection Drugs consumption by region & country, CAGR, 2018-2029 & (K Units)

U.S. VS China: Liver Transplant Anti-Rejection Drugs domestic production, consumption, key domestic manufacturers and share

Global Liver Transplant Anti-Rejection Drugs production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)

Global Liver Transplant Anti-Rejection Drugs production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global Liver Transplant Anti-Rejection Drugs production by Sales Channel production, value, CAGR, 2018-2029, (USD Million) & (K Units).

This reports profiles key players in the global Liver Transplant Anti-Rejection Drugs market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Astellas Pharma Inc., Sanofi Genzyme, Novartis, Asahi Kasei Corporation(Veloxis Pharmaceuticals), Wyeth, Bristol-Myers Squibb Company, Nippon Kayaku and Hansa Biopharma, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Liver Transplant Anti-Rejection Drugs market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Sales Channel. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Liver Transplant Anti-Rejection Drugs Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Liver Transplant Anti-Rejection Drugs Market, Segmentation by Type
Glucocorticoids
Anti-Proliferative Drugs
T Cell Mediated Immunosuppressants

Global Liver Transplant Anti-Rejection Drugs Market, Segmentation by Sales Channel
Hospital
Pharmacy
Online Sales
Medical Institutions

Companies Profiled:
Roche
Astellas Pharma Inc.
Sanofi Genzyme
Novartis
Asahi Kasei Corporation(Veloxis Pharmaceuticals)
Wyeth
Bristol-Myers Squibb Company
Nippon Kayaku
Hansa Biopharma
GSK
AbbVie
Huadong Medicine
North China Pharmaceutical Group
Beijing SL Pharmaceutical
Livzon Pharm
Ruibang Pharmaceutical

Key Questions Answered

1. How big is the global Liver Transplant Anti-Rejection Drugs market?

2. What is the demand of the global Liver Transplant Anti-Rejection Drugs market?

3. What is the year over year growth of the global Liver Transplant Anti-Rejection Drugs market?

4. What is the production and production value of the global Liver Transplant Anti-Rejection Drugs market?

5. Who are the key producers in the global Liver Transplant Anti-Rejection Drugs market?